Rachel M. A. Dang

机构：University of California, Los Angeles, Precision Research (United States) · ORCID：0000-0002-0347-3300

发表论文 11 篇 · 总被引 387 次 · h-index 5

代表论文

• Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial (2023 · Nature Medicine · 被引 289)
• Comparison of newer scoring systems with the conventional scoring systems in general intensive care population. (2012 · PubMed · 被引 46)
• Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment (2023 · Nature Cell Biology · 被引 37)
• CTIM-19. ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL (2023 · Neuro-Oncology · 被引 5)
• ICU scoring systems: which one to use in patients with sepsis? (2011 · Critical Care · 被引 5)
• Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial (2025 · Nature Medicine · 被引 2)